Cel-Sci Corporation - CVM

Cel-Sci Corporation (CVM)
http://www.cel-sci.com/
Coverage: June 13, 2009 - December 13, 2009
Featured: June 13, 2009

The WHO (I'm not kidding- World Health Organization) has officially declared the Swine Flu as a world wide pandemic. This past week, the WHO raised the Swine Flu to "Phase 6", it's highest level for global risk. The Phase 6 alert does not mean the severity is increasing- it means the spread is more global. The Phase 6 ranking opens the door to accelerated production and research on a number of possible therapies and vaccines.

One company getting major recognition for a possible therapy is AMEX listed Cel-Sci (AMEX: CVM), a stock I have been following on and off for many years. Last week, CVM announced its L.E.A.P.S (Ligand Epitope Antigen Presentation System) technology, could represent an immune based therapy for swine flu, and had shown promise. At the Naval Medical Research Center in Silver Spring, MD, L.E.A.P.S has demonstrated an ability to enhance the body's natural protection against many different kinds of diseases. The Navy is focused on using the therapy to treat Malaria. This past week, Cel-Sci announced it was developing an immune based treatment for the Swine Flu, and the stock went absolutely ballistic.

Cel-Sci traded 32 million shares in one day last week, the highest volume in its more than 20 years of being a publicly traded company under the ticker CVM. CVM also surged from about $.25 to $.80 in one day. Pretty crazy.

Latest Newsletter Editions

spacer
Sat, Jan 16, 2010 @ 09:01 am
The Biotech Buzz Rerun I looked for some recent small stock biotech winners. Check out the action in ECTE of late. $1.30 to $2.20 this month on increasing volume as the stock climbs the charts. There's a lot of action in these small biotechs right now. Do you believe in reincarnation? In the stock market...
Wed, Jan 13, 2010 @ 11:01 am
The China/Biotech Buzz It's been a very strong week for my China ideas, with several of the top choices delivering strong news and making new all time highs this week. Review and comments on the hot China ideas below. Biotechs are buzzing right now, and a great number of small cap/biotech stocks are...
Wed, Dec 2, 2009 @ 08:12 am
Coming Attractions You might recall an edition I published about a month ago suggesting it was time to step back, take a look at every idea, and set some cash aside to get past tax selling season and into December. The time has come. I suspect December will be a good month in the markets. Small stocks...
Mon, Nov 9, 2009 @ 02:11 pm
You Asked For It; You'll Get It As expected, lots of you read about my Interclick (NASDAQ: ICLK) idea over the weekend, and sent me the same comment: Why didn't you tell us about this one back in May when it was still under $1 on the Bulletin Board? Point taken- after all, isn't that the goal of investing...
Sat, Oct 10, 2009 @ 04:10 pm
A Couple More Updates: Cel-Sci (AMEX: CVM) and CalAmp (NASDAQ: CAMP) There's lots more action to cover from this past week, so let's get to two more of the actively traded ideas I have shared of late. Cel-Sci (NYSE AMEX: CVM): The Squawking and Finger Pointing Was Inevitable CVM, one of the hottest...

Click Here For More Newsletters on CVM

spacer

Latest Blog Entries

spacer

Quote Data

spacer
Last Trade: 0.70 Bid: 0.0000
Last Size: 0 Ask: 0.0000
Trade Time: 1:35pm Bid x Ask Size: N/A
Change: up arrow +0.0300 (+4.48%) Day's Range: 0.67 - 0.72
Prev Close: 0.6700 52wk Range: 0.54 - 1.90
Open: 0.6700 P/E (ttm): N/A
Volume: 410,254 EPS (ttm): -0.489
spacer [Chart]

Business Summary

spacer
CEL-SCI Corporation, a biotechnology company, engages in research and development of drugs and vaccines for the treatment of cancer and infectious diseases. The company’s primary product Multikine is a patented immunotherapeutic agent consisting of a mixture of naturally occurring cytokines under phase II clinical trail for the treatment of cancer. It also develops CEL-1000 peptide product with its Ligand Epitope Antigen Presentation System technology which is under preclinical stage for the protection/treatment of animals against herpes, malaria, viral encephalitis, and cancer. The company markets its products to cancer centers, physicians, and clinics involved in immunotherapy. CEL-SCI was founded in 1983 and is based in Vienna, Virginia.

Disclosure

spacer
TGR Group LLC, an affiliate of MarketByte LLC, has been paid a fee of 100,000 newly issued restricted shares by Cel-Sci Corporation, for coverage of the Company.

Recent News Headlines

spacer
CEL-SCI Receives Regulatory Clearance to Expand Its Phase III Head and Neck Cancer Trial into Romania
Mon, 26 Jan 2015 14:00:00 GMT
[Business Wire] - CEL-SCI Corporation today announced the Romanian Ministry of Health has cleared the Company to begin patient enrollment and conduct its Phase III head and neck cance
Updated Coverage Report Focuses on CEL-SCI Corporation
Mon, 12 Jan 2015 12:31:25 GMT
[Marketwired] - CEL-SCI Corporation is the subject of an updated coverage report by Acceleron Equity Research, a stock market research firm focused on emerging companies and technologies.
CEL-SCI to Present at Biotech Showcase 2015
Fri, 09 Jan 2015 13:30:00 GMT
[Business Wire] - CEL-SCI Corporation , a late-stage oncology company, announced today that Geert Kersten, Chief Executive Officer, will be presenting at the Biotech Showcase™ 2015 Co
NEW STORY Date Set For Arbitration Trial between CEL-SCI And Clinical Research Organization Inventiv
Tue, 06 Jan 2015 13:14:29 GMT
[at noodls] - DATE SET FOR ARBITRATION TRIAL BETWEEN CEL-SCI AND CLINICAL RESEARCH ORGANIZATION INVENTIV Vienna, VA, January 6, 2015 -- CEL-SCI Corporation (NYSE MKT: CVM) today announced that the trial in its ongoing ...
Date Set for Arbitration Trial Between CEL-SCI and Clinical Research Organization inVentiv
Tue, 06 Jan 2015 13:00:00 GMT
[Business Wire] - CEL-SCI Corporation today announced that the trial in its ongoing arbitration against inVentiv Clinical, LLC (f/k/a PharmaNet, LLC and PharmaNet GmbH (f/k/a PharmaNe
NEW STORY CEL-SCI's 2014 Patient Enrollment Increases Eight-Fold Over 2013 in Its Phase III Head and Neck Cancer Trial
Tue, 06 Jan 2015 04:19:46 GMT
[at noodls] - CEL-SCI's 2014 PATIENT ENROLLMENT INCREASES EIGHT-FOLD OVER 2013 IN ITS PHASE III HEAD AND NECK CANCER TRIAL Vienna, VA, January 5, 2015 -- CEL-SCI Corporation (NYSE MKT: CVM) today announced that in 2014 ...
CEL-SCI’s 2014 Patient Enrollment Increases Eight-Fold over 2013 in its Phase III Head and Neck Cancer Trial
Mon, 05 Jan 2015 13:30:00 GMT
[Business Wire] - CEL-SCI Corporation today announced that in 2014 it enrolled close to 200 patients with advanced primary, not yet treated, head and neck cancer into its global pivotal Phase III head and neck cancer trial for its investigational immunotherapy Multikine* .
CEL SCI CORP Financials
Thu, 01 Jan 2015 18:04:08 GMT
NEW STORY CEL-SCI Reports Fiscal 2014 Financial Results and Clinical & Corporate Developments
Wed, 31 Dec 2014 05:33:26 GMT
[at noodls] - CEL-SCI REPORTS FISCAL 2014 FINANCIAL RESULTS AND CLINICAL & CORPORATE DEVELOPMENTS Vienna, VA, December 23, 2014 -- CEL-SCI Corporation (NYSE MKT: CVM) reported financial results today for the fiscal ...
10-K for CEL-SCI Corp.
Fri, 26 Dec 2014 00:07:36 GMT
CEL SCI CORP Files SEC form 10-K, Annual Report
Tue, 23 Dec 2014 21:46:16 GMT
CEL-SCI Reports Fiscal 2014 Financial Results and Clinical & Corporate Developments
Tue, 23 Dec 2014 21:30:00 GMT
[Business Wire] - CEL-SCI Corporation reported financial results today for the fiscal year ended September 30, 2014. The Company also reported key clinical and corporate developments
NEW STORY CEL-SCI Expands Its Pivotal Phase III Immunotherapy Head and Neck Cancer Trial with Addition of 7 More Clinical Sites
Mon, 08 Dec 2014 14:12:01 GMT
[at noodls] - CEL-SCI EXPANDS ITS PIVOTAL PHASE III IMMUNOTHERAPY HEAD AND NECK CANCER TRIAL WITH ADDITION OF 7 MORE CLINICAL SITES Sites in Europe and Asia add to patient enrollment and position Company to apply for ...
CEL-SCI Expands Its Pivotal Phase III Immunotherapy Head and Neck Cancer Trial With Addition of 7 More Clinical Sites
Mon, 08 Dec 2014 13:45:00 GMT
[Business Wire] - CEL-SCI Corporation today announced that during November it has added seven new clinical sites to its global pivotal Phase III head and neck cancer trial for its investigational immunotherapy Multikine* .
NEW STORY CEL-SCI Quarterly Patient Enrollment in Its Head and Neck Cancer Phase III Trial Increases Eight Fold Over Same Prior Year Period
Tue, 02 Dec 2014 15:01:31 GMT
[at noodls] - CEL-SCI QUARTERLY PATIENT ENROLLMENT IN ITS HEAD AND NECK CANCER PHASE III TRIAL INCREASES EIGHT FOLD OVER SAME PRIOR YEAR PERIOD Vienna, VA, December 2, 2014 -- CEL-SCI Corporation (NYSE MKT: CVM) today ...
CEL-SCI Quarterly Patient Enrollment in Its Head and Neck Cancer Phase III Trial Increases Eight Fold over Same Prior Year Period
Tue, 02 Dec 2014 13:30:00 GMT
[Business Wire] - CEL-SCI Corporation today announced that during the past three months it has enrolled 58 patients with advanced primary, not yet treated, head and neck cancer into its global pivotal Phase III head and neck cancer trial for its investigational immunotherapy Multikine* .
NEW STORY CEL-SCI Enrolls 22 Patients during October in Its Phase III Immunotherapy Head and Neck Cancer Trial
Mon, 03 Nov 2014 15:10:20 GMT
[at noodls] - CEL-SCI ENROLLS 22 PATIENTS DURING OCTOBER IN ITS PHASE III IMMUNOTHERAPY HEAD AND NECK CANCER TRIAL Vienna, VA, November 3, 2014 -- CEL-SCI Corporation (NYSE MKT: CVM) today announced that during the ...
CEL-SCI Enrolls 22 Patients During October in Its Phase III Immunotherapy Head and Neck Cancer Trial
Mon, 03 Nov 2014 13:30:00 GMT
[Business Wire] - CEL-SCI Corporation today announced that during the month of October the Company enrolled 22 patients with advanced primary, not yet treated, head and neck cancer into its global pivotal Phase III head and neck cancer trial for its investigational immunotherapy Multikine* .
NEW STORY CEL-SCI Corporation Announces Closing of Public Offering for Gross Proceeds of $6 Million
Mon, 03 Nov 2014 04:07:28 GMT
[at noodls] - CEL-SCI CORPORATION ANNOUNCES CLOSING OF PUBLIC OFFERING FOR GROSS PROCEEDS OF $6 MILLION Vienna, VA, October 24, 2014 -- CEL-SCI Corporation (NYSE MKT: CVM), a late-stage oncology company, today announced ...
CEL-SCI Corporation Announces Closing of Public Offering for Gross Proceeds of $6 Million
Fri, 24 Oct 2014 14:09:00 GMT
[Business Wire] - CEL-SCI Corporation , a late-stage oncology company, today announced that it has closed an underwritten public offering of 7,894,737 shares of common stock and 1,973,684 warrants to purchase shares of common stock.